Gland Pharma Shares Surge 16% to Record High Amid Market Turmoil: Investment Insights
Gland Pharma share price jumps over 16% to 52-week high despite stock market crash. Should you buy the pharma stock?
Image: Mint
Gland Pharma's share price soared over 16% to a new 52-week high of ₹2,170 despite a significant downturn in the Indian stock market. This increase follows the company's impressive Q4 results, with a 96.6% year-on-year profit surge. Analysts recommend a 'Buy' rating, projecting continued growth driven by product launches and improved profitability.
- 01Gland Pharma's consolidated net profit for Q4 FY26 reached ₹366.6 crore, a 96.6% increase year-on-year.
- 02Revenue for the same quarter grew 22.3% to ₹1,742.7 crore, with the CDMO business contributing 46% of total revenue.
- 03Brokerage firm Motilal Oswal Financial Services raised earnings estimates for FY27 and FY28 by 8% and 10%, respectively.
- 04Equirus Securities projects a 15% EBITDA growth CAGR over FY26–29E, driven by new product launches and improved profitability.
- 05Gland Pharma shares have gained 43% over the past year and 57% over the last three years.
Advertisement
In-Article Ad
Gland Pharma's share price surged over 16% to a new 52-week high of ₹2,170 on the Bombay Stock Exchange (BSE) following the release of strong Q4 results, despite a broader market decline. The company's consolidated net profit for Q4 FY26 rose by 96.6% year-on-year to ₹366.6 crore, bolstered by a 22.3% increase in revenue to ₹1,742.7 crore. The Contract Development and Manufacturing Organization (CDMO) segment was a significant contributor, accounting for 46% of total revenue and growing 36% year-on-year. Analysts from Motilal Oswal Financial Services and Equirus Securities have both issued positive outlooks, with Motilal Oswal raising its earnings estimates and maintaining a 'Buy' rating with a target price of ₹2,300. Equirus anticipates a 15% EBITDA growth CAGR through FY29E, citing new product launches and improved business profitability. Gland Pharma shares have shown robust performance, gaining 43% over the past year and 57% over the last three years.
Advertisement
In-Article Ad
Investors may see potential gains from Gland Pharma's strong performance, which could influence market sentiment positively.
Advertisement
In-Article Ad
Reader Poll
Do you think Gland Pharma shares will continue to rise?
Connecting to poll...
More about Gland Pharma
Nifty Index Declines Amid Global Weakness and Consumer Durables Slide
Business Standard • May 18, 2026
Gland Pharma Shares Surge 16% to Record High Following Strong Q4 Results
Business Standard • May 18, 2026
Gland Pharma Reports 97% Surge in Q4 Profit, Driving Stock Up 12.37%
Business Standard • May 18, 2026
Read the original article
Visit the source for the complete story.